Table 1.

Potency of hu3F8-BsAb

Tumor typeCell lineGD2 expression (MFI)aEC50 (ng/mL)bEC50
NeuroblastomaLAN-11,4670.00094.5 fmol/L
NeuroblastomaNMB71,4760.0015 fmol/L
NeuroblastomaIMR321,2290.00525 fmol/L
MelanomaHT-1441,2270.01680 fmol/L
SCLCNCI-H5242,4370.02100 fmol/L
MelanomaSKMEL15760.05250 fmol/L
MelanomaM147450.08400 fmol/L
NeuroblastomaSKNBE(1)N5090.08400 fmol/L
OsteosarcomaU2OS2830.31.5 pmol/L
NeuroblastomaSKNBE(2)C4780.52.5 pmol/L
OsteosarcomaCRL14273710.84 pmol/L
SCLCNCI-H692320.84 pmol/L
NeuroblastomaSKNJB196210 pmol/L
MelanomaSKMEL2824420 pmol/L
NeuroblastomaSKNJC22820100 pmol/L
Breast carcinomaMCF7621105 pmol/L
EwingSKEAW102150750 pmol/L
SCLCNCI-H345383201.6 nmol/L
Colon carcinomaSW62067003.5 nmol/L
Breast carcinomaAU5658>1,000>5 nmol/L
Breast carcinomaMDA-MB-3616>1,000>5 nmol/L
Breast carcinomaSKBR37>1,000>5 nmol/L
Breast carcinomaMDA-MB-2315>1,000>5 nmol/L
Breast carcinomaMDA-MB-4686>1,000>5 nmol/L
EwingSKES-124>1,000>5 nmol/L
Ovarian carcinomaOVCAR34>1,000>5 nmol/L
Ovarian carcinomaSKOV35>1,000>5 nmol/L
RhabdomyosarcomaHTB828>1,000>5 nmol/L

Abbreviation: MFI, mean fluorescence intensity.

  • aFACS analysis using hu3F8 IgG1, with rituximab as negative control (MFI set at 5).

  • bFour-hour 51Cr release assay at 10:1 E:T ratio. Maximum antibody concentration at 1 μg/mL. EC50 (concentration of antibody at half maximal killing) was calculated using SigmaPlot.